1

2

3
James Doherty
Dorn Conrad P, Finke Paul E, Maccoss Malcolm, Doherty James B, Shah Shrenik K, Hagmann William K: New substituted azetidinones as anti-inflammatory and antidegenerative agents.. Merck & Co, April 22, 1992: EP0481671-A1 (40 worldwide citation)

New substituted azetidinones of the general formula (A') which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. e


4
Chang Linda L, Delaszlo Stephen E, Hagmann William K, Kamenecka Theodore M: Aryl amides as cell adhesion inhibitors. Merck &Amp, Co, March 28, 2001: GB2354440-A (28 worldwide citation)

A method for the prevention or treatment of diseases, disorders, conditions or symptoms mediated by cell adhesion in a mammal comprises the administration of an effective amount of a compound of Formula I. The disease may be selected from asthma, allergic rhinitis, multiple sclerosis and inflammator ...


5
Chapman Kevin T, Thornberry Nancy A, Maccoss Malcolm, Weidner Jeffrey R, Mumford Richard A, Hagmann William K: Novel chromophore containing compounds.. Merck & Co, February 24, 1993: EP0528487-A2 (25 worldwide citation)

Disclosed are novel chromophore containing compounds of Formula I and their use in determining interleukin-1 beta convertase (ICE) activity. ICE has been implicated in inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; ...


6
Kopka Ihor E, Li Bing, Hagmann William K: Substituted pyrimidines. Merck & Co, Kopka Ihor E, Li Bing, Hagmann William K, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, April 8, 2004: WO/2004/029204 (23 worldwide citation)

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs ...


7
Doherty James B, Finke Paul E, Firestone Raymond A, Hagmann William K, Shah Shrenik K, Thompson Kevan R: New substituted cephalosporin sulfones as antiinflammatory and antidegenerative agents, pharmaceutical compositions containing the same and processes for making them.. Merck & Co, November 7, 1984: EP0124081-A2 (19 worldwide citation)

New substituted cephalosporin sulfones are disclosed having the structural formula: wherein M is, e.g., trifluoromethyl, chloro or fluoro or -COOH; R1 is, e.g., hydrogen, hydroxy, mercapto, substituted oxy, substituted thio, hydrocarbyl or substituted hydrocarbyl group; B is OB1, or NB2B3 wherein B1 ...


8
Doherty James B, Finke Paul E, Firestone Raymond A, Hagmann William K, Thompson Kevan R, Shah Shrenik K: New substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents.. Merck & Co, May 18, 1988: EP0267723-A2 (15 worldwide citation)

New substituted cephalosporin sulfones with structural formula: are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.


9
Hanlon William A, Mumford Richard A, Humes John L, Maccoss Malcolm, Knight Wilson B, Finke Paul E, Hagmann William K, Shah Shrenik K: Assay for evaluating inhibition of pmn elastase by n-substituted azetidinones.. Merck & Co, March 3, 1993: EP0529719-A1 (10 worldwide citation)

N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with t ...


10
Burns Donald H, Chen Alex M, Gibson Raymond E, Goulet Mark T, Hagmann William K, Hamill Terence G, Jewell James P, Lin Linus S, Liu Ping, Peresypkin Andrey V: Radiolabeled cannabinoid-1 receptor modulators. Merck & Co, Burns Donald H, Chen Alex M, Gibson Raymond E, Goulet Mark T, Hagmann William K, Hamill Terence G, Jewell James P, Lin Linus S, Liu Ping, Peresypkin Andrey V, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, February 3, 2005: WO/2005/009479 (9 worldwide citation)

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabe ...



Click the thumbnails below to visualize the patent trend.